Fatty Liver Disease Council
Born from the urgent need to give patients a voice in liver health, the Fatty Liver Disease Council, formerly the NASH Council, was established to unite organizations and stakeholders in a shared mission to identify gaps, address critical public health issues, and champion patient-focused solutions. The council includes patient advocacy groups, medical societies, and government agencies – champions fatty liver disease as a prominent public health concern. The Council advocates for patient priorities, amplifying the voice of the liver disease community in key regulatory and legislative realms.
View our Fatty Liver Disease Council members:
RESOURCES:
Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient-Focused Drug Development (EL-PFDD) Report
Co-developed on November 4, 2021 with members of the Fatty Liver Disease Council (formerly known as NASH council), patient advocacy organizations, and GLI’s Liver Action Network, the NASH EL-PFDD brings together survey findings and testimony from clinicians, patients, and caregivers to capture the lived experience of metabolic dysfunction-associated steatohepatitis (MASH/NASH). These insights are designed to ensure that the patient and caregiver perspective is directly reflected in FDA review processes, treatment development, and future regulatory decision-making.
